Palmoplantar	B:C0030246
pustulosis	I:C0030246
-	O
a	O
cross-sectional	O
analysis	I:C0010362
in	O
Germany	O
.	O

Palmoplantar	O
pustulosis	I:C0030246
-	O
a	O
cross-sectional	B:C0010362
analysis	I:C0010362
in	O
Germany	O
.	O

Palmoplantar	O
pustulosis	I:C0030246
-	O
a	O
cross-sectional	O
analysis	I:C0010362
in	O
Germany	B:C0017480
.	O

Palmoplantar	B:C0030246
pustulosis	I:C0030246
(	O
Palmoplantar	O
pustulosis	I:C0030246
)	O
is	O
a	O
recalcitrant	O
chronic	O
inflammatory	O
skin	I:C3875321
disease	I:C3875321
.	O

Palmoplantar	O
pustulosis	I:C0030246
(	O
Palmoplantar	B:C0030246
pustulosis	I:C0030246
)	O
is	O
a	O
recalcitrant	O
chronic	O
inflammatory	O
skin	I:C3875321
disease	I:C3875321
.	O

Palmoplantar	O
pustulosis	I:C0030246
(	O
Palmoplantar	O
pustulosis	I:C0030246
)	O
is	O
a	O
recalcitrant	O
chronic	O
inflammatory	B:C3875321
skin	I:C3875321
disease	I:C3875321
.	O

Data	O
relevant	O
for	O
the	O
medical	B:C0496675
care	I:C0496675
of	O
patients	O
with	O
Palmoplantar	O
pustulosis	I:C0030246
are	O
scarce	O
.	O

Data	O
relevant	O
for	O
the	O
medical	O
care	I:C0496675
of	O
patients	O
with	O
Palmoplantar	B:C0030246
pustulosis	I:C0030246
are	O
scarce	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
disease	O
burden	O
,	O
clinical	O
characteristics	O
,	O
and	O
comorbidity	O
of	O
Palmoplantar	B:C0030246
pustulosis	I:C0030246
patients	O
in	O
Germany	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
disease	O
burden	O
,	O
clinical	O
characteristics	O
,	O
and	O
comorbidity	O
of	O
Palmoplantar	O
pustulosis	I:C0030246
patients	O
in	O
Germany	B:C0017480
.	O

Palmoplantar	B:C0030246
pustulosis	I:C0030246
patients	O
were	O
examined	O
in	O
a	O
crosssectional	O
study	O
at	O
seven	O
specialized	O
psoriasis	I:C1708333
centers	I:C1708333
in	O
Germany	O
.	O

Palmoplantar	O
pustulosis	I:C0030246
patients	O
were	O
examined	O
in	O
a	O
crosssectional	O
study	O
at	O
seven	O
specialized	B:C1708333
psoriasis	I:C1708333
centers	I:C1708333
in	O
Germany	O
.	O

Palmoplantar	O
pustulosis	I:C0030246
patients	O
were	O
examined	O
in	O
a	O
crosssectional	O
study	O
at	O
seven	O
specialized	O
psoriasis	I:C1708333
centers	I:C1708333
in	O
Germany	B:C0017480
.	O

Of	O
the	O
172	O
included	O
patients	O
with	O
Palmoplantar	B:C0030246
pustulosis	I:C0030246
,	O
79.1	O
%	O
were	O
female	O
and	O
69.8	O
%	O
were	O
smokers	O
.	O

Of	O
the	O
172	O
included	O
patients	O
with	O
Palmoplantar	O
pustulosis	I:C0030246
,	O
79.1	O
%	O
were	O
female	B:C0043210
and	O
69.8	O
%	O
were	O
smokers	O
.	O

Of	O
the	O
172	O
included	O
patients	O
with	O
Palmoplantar	O
pustulosis	I:C0030246
,	O
79.1	O
%	O
were	O
female	O
and	O
69.8	O
%	O
were	O
smokers	B:C0337664
.	O

In	O
addition	O
,	O
25.0	O
%	O
suffered	O
from	O
psoriasis	B:C0263361
vulgaris	I:C0263361
,	O
28.2	O
%	O
had	O
documented	O
psoriatic	O
arthritis	I:C0003872
,	O
and	O
30.2	O
%	O
had	O
a	O
family	O
history	I:C0455439
of	I:C0455439
psoriasis	I:C0455439
.	O

In	O
addition	O
,	O
25.0	O
%	O
suffered	O
from	O
psoriasis	O
vulgaris	I:C0263361
,	O
28.2	O
%	O
had	O
documented	O
psoriatic	B:C0003872
arthritis	I:C0003872
,	O
and	O
30.2	O
%	O
had	O
a	O
family	O
history	I:C0455439
of	I:C0455439
psoriasis	I:C0455439
.	O

In	O
addition	O
,	O
25.0	O
%	O
suffered	O
from	O
psoriasis	O
vulgaris	I:C0263361
,	O
28.2	O
%	O
had	O
documented	O
psoriatic	O
arthritis	I:C0003872
,	O
and	O
30.2	O
%	O
had	O
a	O
family	B:C0455439
history	I:C0455439
of	I:C0455439
psoriasis	I:C0455439
.	O

In	O
77	O
patients	O
the	O
mean	O
Dermatology	B:C0451112
Life	I:C0451112
Quality	I:C0451112
Index	I:C0451112
(	O
Dermatology	O
Life	I:C0451112
Quality	I:C0451112
Index	I:C0451112
)	O
was	O
12.2	O
±	O
7.7	O
(	O
mean	O
±	O
SD	O
)	O
.	O

In	O
77	O
patients	O
the	O
mean	O
Dermatology	O
Life	I:C0451112
Quality	I:C0451112
Index	I:C0451112
(	O
Dermatology	B:C0451112
Life	I:C0451112
Quality	I:C0451112
Index	I:C0451112
)	O
was	O
12.2	O
±	O
7.7	O
(	O
mean	O
±	O
SD	O
)	O
.	O

The	O
mean	O
Psoriasis	B:C0033860
Palmoplantar	O
Pustulosis	I:C0030246
Area	O
and	O
Severity	O
Index	O
(	O
PPPASI	O
)	O
was	O
12.6	O
±	O
8.6	O
.	O

The	O
mean	O
Psoriasis	O
Palmoplantar	B:C0030246
Pustulosis	I:C0030246
Area	O
and	O
Severity	O
Index	O
(	O
PPPASI	O
)	O
was	O
12.6	O
±	O
8.6	O
.	O

Mean	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
was	O
above	O
average	O
at	O
27.1	O
±	O
5.5	O
.	O

The	O
Palmoplantar	B:C0030246
pustulosis	I:C0030246
patients	O
had	O
previously	O
received	O
an	O
average	O
of	O
2.6	O
±	O
2.1	O
different	O
anti-psoriatic	O
systemic	I:C1516001
drugs	I:C1516001
or	O
UV	O
-	I:C0041626
therapies	I:C0041626
.	O

The	O
Palmoplantar	O
pustulosis	I:C0030246
patients	O
had	O
previously	O
received	O
an	O
average	O
of	O
2.6	O
±	O
2.1	O
different	O
anti-psoriatic	B:C1516001
systemic	I:C1516001
drugs	I:C1516001
or	O
UV	O
-	I:C0041626
therapies	I:C0041626
.	O

The	O
Palmoplantar	O
pustulosis	I:C0030246
patients	O
had	O
previously	O
received	O
an	O
average	O
of	O
2.6	O
±	O
2.1	O
different	O
anti-psoriatic	O
systemic	I:C1516001
drugs	I:C1516001
or	O
UV	B:C0041626
-	I:C0041626
therapies	I:C0041626
.	O

The	O
systemic	O
drugs	B:C1254351
that	O
had	O
been	O
used	O
most	O
frequently	O
were	O
corticosteroids	O
in	O
40.1	O
%	O
of	O
patients	O
,	O
followed	O
by	O
acitretin	O
(	O
37.8	O
%	O
)	O
,	O
and	O
methotrexate	O
(	O
27.9	O
%	O
)	O
.	O

The	O
systemic	O
drugs	O
that	O
had	O
been	O
used	O
most	O
frequently	O
were	O
corticosteroids	B:C0001617
in	O
40.1	O
%	O
of	O
patients	O
,	O
followed	O
by	O
acitretin	O
(	O
37.8	O
%	O
)	O
,	O
and	O
methotrexate	O
(	O
27.9	O
%	O
)	O
.	O

The	O
systemic	O
drugs	O
that	O
had	O
been	O
used	O
most	O
frequently	O
were	O
corticosteroids	O
in	O
40.1	O
%	O
of	O
patients	O
,	O
followed	O
by	O
acitretin	B:C0050559
(	O
37.8	O
%	O
)	O
,	O
and	O
methotrexate	O
(	O
27.9	O
%	O
)	O
.	O

The	O
systemic	O
drugs	O
that	O
had	O
been	O
used	O
most	O
frequently	O
were	O
corticosteroids	O
in	O
40.1	O
%	O
of	O
patients	O
,	O
followed	O
by	O
acitretin	O
(	O
37.8	O
%	O
)	O
,	O
and	O
methotrexate	B:C0025677
(	O
27.9	O
%	O
)	O
.	O

The	O
PPPASI	O
was	O
13.4	O
±	O
8.9	O
in	O
patients	O
without	O
current	O
systemic	B:C1515119
therapy	I:C1515119
and	O
10.4	O
±	O
7.9	O
in	O
patients	O
with	O
systemic	O
therapy	I:C1515119
.	O

The	O
PPPASI	O
was	O
13.4	O
±	O
8.9	O
in	O
patients	O
without	O
current	O
systemic	O
therapy	I:C1515119
and	O
10.4	O
±	O
7.9	O
in	O
patients	O
with	O
systemic	B:C1515119
therapy	I:C1515119
.	O

Many	O
Palmoplantar	B:C0030246
pustulosis	I:C0030246
patients	O
had	O
a	O
concomitant	O
diagnosis	O
of	O
psoriasis	O
vulgaris	I:C0263361
and	O
/	O
or	O
psoriatic	O
arthritis	I:C0003872
or	O
had	O
a	O
family	O
history	I:C0455439
of	I:C0455439
psoriasis	I:C0455439
.	O

Many	O
Palmoplantar	O
pustulosis	I:C0030246
patients	O
had	O
a	O
concomitant	O
diagnosis	B:C0011900
of	O
psoriasis	O
vulgaris	I:C0263361
and	O
/	O
or	O
psoriatic	O
arthritis	I:C0003872
or	O
had	O
a	O
family	O
history	I:C0455439
of	I:C0455439
psoriasis	I:C0455439
.	O

Many	O
Palmoplantar	O
pustulosis	I:C0030246
patients	O
had	O
a	O
concomitant	O
diagnosis	O
of	O
psoriasis	B:C0263361
vulgaris	I:C0263361
and	O
/	O
or	O
psoriatic	O
arthritis	I:C0003872
or	O
had	O
a	O
family	O
history	I:C0455439
of	I:C0455439
psoriasis	I:C0455439
.	O

Many	O
Palmoplantar	O
pustulosis	I:C0030246
patients	O
had	O
a	O
concomitant	O
diagnosis	O
of	O
psoriasis	O
vulgaris	I:C0263361
and	O
/	O
or	O
psoriatic	B:C0003872
arthritis	I:C0003872
or	O
had	O
a	O
family	O
history	I:C0455439
of	I:C0455439
psoriasis	I:C0455439
.	O

Many	O
Palmoplantar	O
pustulosis	I:C0030246
patients	O
had	O
a	O
concomitant	O
diagnosis	O
of	O
psoriasis	O
vulgaris	I:C0263361
and	O
/	O
or	O
psoriatic	O
arthritis	I:C0003872
or	O
had	O
a	O
family	B:C0455439
history	I:C0455439
of	I:C0455439
psoriasis	I:C0455439
.	O

Despite	O
the	O
fact	O
that	O
many	O
of	O
the	O
patients	O
were	O
using	O
anti-psoriatic	O
therapies	O
,	O
there	O
was	O
still	O
a	O
high	O
burden	O
of	O
disease	O
within	O
this	O
Palmoplantar	B:C0030246
pustulosis	I:C0030246
cohort	O
.	O

This	O
insufficient	O
control	B:C1274136
of	I:C1274136
symptoms	I:C1274136
demonstrates	O
the	O
urgent	O
need	O
for	O
new	O
Palmoplantar	O
pustulosis	I:C0030246
treatments	O
.	O

This	O
insufficient	O
control	O
of	I:C1274136
symptoms	I:C1274136
demonstrates	O
the	O
urgent	O
need	O
for	O
new	O
Palmoplantar	B:C0030246
pustulosis	I:C0030246
treatments	O
.	O

This	O
insufficient	O
control	O
of	I:C1274136
symptoms	I:C1274136
demonstrates	O
the	O
urgent	O
need	O
for	O
new	O
Palmoplantar	O
pustulosis	I:C0030246
treatments	B:C0087111
.	O

